Consensus Perrigo Company plc

Equities

PRGO

IE00BGH1M568

Real-time Estimate Cboe BZX Other stock markets 03:06:15 2024-04-23 pm EDT			5-day change	1st Jan Change
30.42 ^USD	+1.18%		+1.77%	-5.25%

Apr. 08	Piper Sandler Raises Perrigo's Price Target to $39 From $35, Maintains Overweight Rating	MT
Apr. 04	CVS Caremark to cover Perrigo's birth control pill in US at zero cost for plan sponsors	RE

Evolution of the average Target Price on Perrigo Company plc

Price target over the last 5 years

History of analyst recommendation changes

d36ccc6a31fa4c.LTCVVg4JPPGyjbIb1ccIfMXzOHH2lvZgU052LtS3OEE.FVjMEl1wC6TzwN5Tl4g6RPOHaRa4xJk0JztGRuTcZyVVYMwee35RhfHF-w~387e3e47896f1c2991cf422ee52b47f6

Analyst Recommendations on Perrigo Company plc

Piper Sandler Raises Perrigo's Price Target to $39 From $35, Maintains Overweight Rating	Apr. 08	MT
CVS Caremark to cover Perrigo's birth control pill in US at zero cost for plan sponsors	Apr. 04	RE
Multiple CVS Caremark Plans to Cover Perrigo's Opill at No Cost	Apr. 04	MT
JPMorgan Cuts Price Target on Perrigo to $41 From $48, Maintains Overweight Rating	Feb. 28	MT
Canaccord Genuity Starts Perrigo at Buy With $49 Price Target	23-03-07	MT
Raymond James Adjusts Perrigo Price Target to $43 From $42, Maintains Outperform Rating	23-03-06	MT
Raymond James Adjusts Price Target on Perrigo Company to $42 From $48, Maintains Outperform Rating	22-11-09	MT
Argus Upgrades Perrigo to Buy From Hold; Price Target is $46	22-09-14	MT
Wells Fargo Raises Perrigo to Overweight From Equalweight, Price Target to $54 From $48	22-09-06	MT
PERRIGO REPORTS FIRST QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS, RAISES GUIDANCE	22-05-11	PR
Raymond James Adjusts Perrigo's Price Target to $48 from $55, Keeps Outperform Rating	22-05-04	MT
Raymond James Adjusts Price Target on Perrigo to $55 From $59, Maintains Outperform Rating	21-11-11	MT
PERRIGO : Raymond James Upgrades Perrigo to Outperform from Market Perform, Sets $59 Price Target	21-10-14	MT
PERRIGO : Jefferies Upgrades Perrigo to Buy from Hold, Adjusts PT to $63 from $45	21-09-30	MT
PERRIGO : Jefferies Upgrades Perrigo to Buy from Hold, Adjusts Price Target to $63 from $45	21-09-30	MT
PERRIGO : RBC Cuts Price Target on Perrigo to $48 From $51 After Q2 Results Miss Expectations; Sector Perform Rating Maintained	21-08-12	MT
Health Care Slips As Traders Rotate Into Rate-Sensitive Sectors -- Health Care Roundup	21-08-11	DJ
PERRIGO : Morgan Stanley Adjusts Perrigo Company PT to $45 From $53, Maintains Equal Weight Rating	21-03-05	MT
PERRIGO : RBC Capital Adjusts Perrigo's Price Target to $51 From $49, Maintains Sector Perform Rating	21-03-02	MT
PERRIGO : RBC Capital Downgrades Perrigo Company to Sector Perform From Outperform, Adjusts PT to $49 From $59	21-01-06	MT
Perrigo and Catalent Announce FDA Approval of Perrigo's AB-rated Generic Version of ProAir HFA	20-02-24	CI
Perrigo Company plc Announces the Relaunch of the AB Rated Generic Version of Transderm Scop 1.5 Mg	19-10-03	CI
Perrigo Company plc Announces FDA Final Approval and Launch of the AB-Rated Generic Version of Metrogel-Vaginal Gel	19-07-03	CI
Perrigo Announces FDA Final Approval for AB Rated Generic Version of Voltaren® Gel 1%	19-05-21	CI
Perrigo Announces FDA Final Approval for its AB Rated Generic Version of Zovirax® Cream 5%	19-02-06	CI